An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer.

 

Trial Summary:

The ICON8 trial is testing whether giving chemotherapy at the smaller dose more often is better than the traditional once every 3 weeks that has been the norm for many years.

Supported By:

MRC (UK) and Cancer Australia

Eligibility:

Women with newly diagnosed high-risk early stage or advanced stage epithelial, fallopian tube or primary peritoneal carcinoma, and ovarian carcinosarcoma.

Registration ID:

NCT01654146

Participation:

International

Australian Lead Group:

ANZGOG

Status:

Open

Activation Date:

27/11/2013

Chairs:

Andrew Dean (Australia)

Contact:

icon8.study@sydney.edu.au